Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1

DSpace/Manakin Repository

Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1

Citable link to this page

 

 
Title: Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1
Author: Gohda, Tomohito; Skupien, Jan; Smiles, Adam M.; Holak, Rita R.; McDonnell, Kevin P.; Lee, Jung Eun; Walker, William H.; Jeong, Jackson; Krolewski, Andrzej Stefan; Niewczas, Monika Anna

Note: Order does not necessarily reflect citation order of authors.

Citation: Lee, Jung Eun, Tomohito Gohda, William H. Walker, Jan Skupien, Adam M. Smiles, Rita R. Holak, Jackson Jeong, Kevin P. McDonnell, Andrzej Stefan Krolewski, and Monika Anna Niewczas. 2013. Risk of ESRD and all cause mortality in Type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS ONE 8(3): e58007.
Full Text & Related Files:
Abstract: Introduction: Recent studies demonstrated that circulating fibroblast growth factor (FGF)-23 was associated with risk of end stage renal disease (ESRD) and mortality. This study aims to examine whether the predictive effect of FGF-23 is independent from circulating levels of tumor necrosis factor receptor 1 (TNFR1), a strong predictor of ESRD in Type 2 diabetes (T2D). Methods: We studied 380 patients with T2D who were followed for 8–12 years and were used previously to examine the effect of TNFR1. Baseline plasma FGF-23 was measured by immunoassay. Results: During follow-up, 48 patients (13%) developed ESRD and 83 patients (22%) died without ESRD. In a univariate analysis, baseline circulating levels of FGF-23 and TNFR1 were significantly higher in subjects who subsequently developed ESRD or died without ESRD than in those who remained alive. In a Cox proportional hazard model, baseline concentration of FGF-23 was associated with increased risk of ESRD, however its effect was no longer significant after controlling for TNFR1 and other clinical characteristics (HR 1.3, p = 0.15). The strong effect of circulating level of TNFR1 on risk of ESRD was not changed by including circulating levels of FGF-23 (HR 8.7, p<0.001). In the Cox multivariate model, circulating levels of FGF-23 remained a significant independent predictor of all-cause mortality unrelated to ESRD (HR 1.5, p<0.001). Conclusions: We demonstrated that the effect of circulating levels of FGF-23 on the risk of ESRD is accounted for by circulating levels of TNFR1. We confirmed that circulating levels of FGF-23 have an independent effect on all-cause mortality in T2D.
Published Version: doi:10.1371/journal.pone.0058007
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603950/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10622952
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters